Cancers such as lung cancer, head and neck cancer, and melanoma have exhibited clinical benefit with IO, although patients who are never smokers (i.e., ALK, ROS, and RET) or whose tumors express mutant EGFR showed 0–14% response rates, irrespective of PD-L1 expression levels57. This evidence concerns the gene ALK and melanoma.